Literature DB >> 27693181

Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease.

Ruiqing Ni1, Per-Göran Gillberg1, Nenad Bogdanovic2, Matti Viitanen3, Liisa Myllykangas4, Inger Nennesmo5, Bengt Långström6, Agneta Nordberg7.   

Abstract

INTRODUCTION: Amyloid imaging has been integrated into diagnostic criteria for Alzheimer's disease (AD). How amyloid tracers binding differ for different tracer structures and amyloid-β aggregates in autosomal dominant AD (ADAD) and sporadic AD is unclear.
METHODS: Binding properties of different amyloid tracers were examined in brain homogenates from six ADAD with APPswe, PS1 M146V, and PS1 EΔ9 mutations, 13 sporadic AD, and 14 control cases.
RESULTS: 3H-PIB, 3H-florbetaben, 3H-AZD2184, and BTA-1 shared a high- and a varying low-affinity binding site in the frontal cortex of sporadic AD. AZD2184 detected another binding site (affinity 33 nM) in the frontal cortex of ADAD. The 3H-AZD2184 and 3H-PIB binding were significantly higher in the striatum of ADAD compared to sporadic AD and control. Polyphenol resveratrol showed strongest inhibition on 3H-AZD84 binding followed by 3H-florbetaben and minimal on 3H-PIB. DISCUSSION: This study implies amyloid tracers of different structures detect different sites on amyloid-β fibrils or conformations.
Copyright © 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AZD2184; Alzheimer's disease; Amyloid-β; Autosomal dominant Alzheimer's disease; Florbetaben; Pittsburgh compound B; Positron emission tomography; Resveratrol

Mesh:

Substances:

Year:  2016        PMID: 27693181     DOI: 10.1016/j.jalz.2016.08.006

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  9 in total

1.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

2.  Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice.

Authors:  Ruiqing Ni; Zhenyue Chen; Xosé Luís Deán-Ben; Fabian F Voigt; Daniel Kirschenbaum; Gloria Shi; Alessia Villois; Quanyu Zhou; Alessandro Crimi; Paolo Arosio; Roger M Nitsch; K Peter R Nilsson; Adriano Aguzzi; Fritjof Helmchen; Jan Klohs; Daniel Razansky
Journal:  Nat Biomed Eng       Date:  2022-07-14       Impact factor: 29.234

3.  Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography.

Authors:  Wuwei Ren; Linlin Li; Jianru Zhang; Markus Vaas; Jan Klohs; Jorge Ripoll; Martin Wolf; Ruiqing Ni; Markus Rudin
Journal:  Biomed Opt Express       Date:  2022-06-08       Impact factor: 3.562

4.  Letter.

Authors:  Ara S Khachaturian
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-21

Review 5.  Magnetic Resonance Imaging in Animal Models of Alzheimer's Disease Amyloidosis.

Authors:  Ruiqing Ni
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

Review 6.  Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.

Authors:  Cinzia Maschio; Ruiqing Ni
Journal:  Front Aging Neurosci       Date:  2022-04-22       Impact factor: 5.702

Review 7.  Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.

Authors:  Ruiqing Ni; Roger M Nitsch
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

Review 8.  PET Imaging of Neuroinflammation in Alzheimer's Disease.

Authors:  Rong Zhou; Bin Ji; Yanyan Kong; Limei Qin; Wuwei Ren; Yihui Guan; Ruiqing Ni
Journal:  Front Immunol       Date:  2021-09-16       Impact factor: 7.561

Review 9.  Multi-scale optoacoustic molecular imaging of brain diseases.

Authors:  Daniel Razansky; Jan Klohs; Ruiqing Ni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-16       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.